Key result
Atorvastatin linked to a case of thrombocytopenic purpura resolving upon discontinuation and steroid treatment.
Why the study?
Thrombocytopenic purpura secondary to atorvastatin is a rare idiosyncratic reaction requiring clinical recognition and management.
Does atorvastatin cause thrombocytopenic purpura in a patient with ischaemic heart disease?
Case Report (n=1)
Does atorvastatin cause thrombocytopenic purpura in a patient with ischaemic heart disease?
Atorvastatin may cause an idiosyncratic reaction leading to thrombocytopenic purpura, which can resolve upon discontinuation and steroid treatment.
Answers are grounded in this paper and cite their sources.
Clinicians should consider atorvastatin in unexplained thrombocytopenic purpura; this case leaves open the need for confirmatory evidence.
A 44-year-old male patient with a single vessel ischaemic heart disease was referred to the lipid clinic for management of hypercholesterolaemia after an episode of admission with thrombocytopenic purpura secondary to atorvastatin. Atorvastatin was discontinued and his platelet counts improved gradually with steroids. He is now established on a different statin with no further episodes of thrombocytopenia. Though a drug challenge was never done, an idiosyncratic reaction to the initial statin seems to be the most likely cause.
No takes yet. Share an insight, caveat, or question.
Narayanan et al. (2010) conducted a case report in Thrombocytopenic purpura (n=1). Atorvastatin was evaluated on Thrombocytopenic purpura. Atorvastatin exposure was identified as the likely cause of thrombocytopenic purpura in a 44-year-old male, which resolved upon discontinuation and steroid treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: